CCL2 and myeloid sarcoma: The analytes HGF, Eotaxin/CCL11, MCP-1/CCL2 and Rantes/CCL5 were present at significantly lower circulating levels in the RR-MS patients than in the progressive clinical forms of MS patients (SP-MS and PP-MS).